Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Banner MD Anderson Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Stanford Medicine, Stanford University, Washington University in St. Louis, Albert Einstein College of Medicine, Montefiore Medical Center, Kite (United States), Moffitt Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2958449555